U.S. pharma huge copyright scrapped two experimental weight loss tablets past yr—a when-everyday capsule, lotiglipron, because of elevated liver enzymes and a 2 times-each day pill, danuglipron, because of sturdy Unwanted side effects—but CEO Albert Bourla has said the company is decided to “play and earn” while in the being overweight spac